ConjuChem's IPO

ConjuChem raised a round of funding on December 02, 2000. Investors include Public.

ConjuChem creates next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Construct (DAC) and Pre…

Articles about ConjuChem's IPO: